Publications by authors named "A M Larocca"
Introduction: In the OPTIMISMM trial, pomalidomide/bortezomib/dexamethasone (PVd) significantly prolonged median progression-free survival (PFS) versus bortezomib/dexamethasone (Vd) in lenalidomide-exposed relapsed and refractory multiple myeloma (RRMM). We report final overall survival (OS) and updated efficacy analyses.
Methods: Adults with RRMM who had 1-3 prior regimens, including lenalidomide (≥ 2 cycles), were assigned (1:1) to PVd or Vd.
Targeted immunotherapy combinations, including the anti-CD38 monoclonal antibody (MoAb) daratumumab, have shown promising results in patients with relapsed/refractory multiple myeloma (RRMM), leading to a considerable increase in progression-free survival. However, a large fraction of patients inevitably relapse. To understand this, we investigated 32 relapsed MM patients treated with daratumumab, lenalidomide, and dexamethasone (Dara-Rd; NCT03848676).
View Article and Find Full Text PDFArticle Synopsis
- Osilodrostat is a new oral medication approved for treating adults with Cushing's syndrome, particularly for those who haven't had success with surgery.
- Clinical studies have shown it effectively lowers cortisol levels and improves various health aspects like body weight, blood pressure, and overall quality of life.
- It has a favorable safety profile and could be used at various stages of Cushing's syndrome treatment, including pre-surgery, post-surgery, and as a first-line or second-line treatment option.